Research-only content. This comparison is for educational purposes and does not constitute medical advice. Read full disclaimer →

MOTS-c vs SS-31

Last updated: 2026-05-21

MOTS-c is a mitochondrial-derived peptide encoded by mitochondrial DNA; SS-31 (Elamipretide) is a synthetic peptide that targets cardiolipin in the inner mitochondrial membrane.
MOTS-c research focuses on metabolic regulation and exercise mimetic effects; SS-31 research emphasizes mitochondrial dysfunction and cardioprotection.
SS-31 has advanced further in clinical trials, including Phase 2/3 studies for Barth syndrome and heart failure.
MOTS-c activates AMPK and influences glucose metabolism; SS-31 stabilizes the electron transport chain by binding cardiolipin.
Both represent a growing field of mitochondria-targeted peptide therapeutics.

MOTS-c and SS-31 both target mitochondrial function but through entirely different mechanisms — MOTS-c as an endogenous signaling peptide and SS-31 as a synthetic membrane-targeting compound.

Side-by-Side Comparison

Attribute	MOTS-c	SS-31
What It Is	A mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity.	A mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic.
Typical Research Focus
Proposed Mechanisms	Not yet documented	Not yet documented
Evidence Snapshot	Low Evidenceresearch peptide	High Evidenceprescription drug
Cautions	Discovery is recent; most data is preclinical No completed human clinical trials Long-term effects unknown	FDA-approved only for Barth syndrome; other indications remain investigational Accelerated approval pathway — confirmatory trials may be required Off-label use for anti-aging or longevity not supported by clinical evidence

MOTS-c

What It Is: A mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity.
Research Focus
Evidence: Low Evidence
Cautions: Discovery is recent; most data is preclinical

No completed human clinical trials

Long-term effects unknown

SS-31

What It Is: A mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic.
Research Focus
Evidence: High Evidence
Cautions: FDA-approved only for Barth syndrome; other indications remain investigational

Accelerated approval pathway — confirmatory trials may be required

Off-label use for anti-aging or longevity not supported by clinical evidence

When Researchers Compare Them

MOTS-c and SS-31 represent two distinct approaches to mitochondrial therapeutics. MOTS-c is an endogenous mitochondrial-derived peptide (MDP), meaning it is naturally encoded within mitochondrial DNA. Research has shown it activates AMPK, enhances glucose uptake, and may function as an exercise mimetic — making it a subject of interest in metabolic disease and aging research.

SS-31 (also known as Elamipretide or Bendavia) is a synthetic tetrapeptide designed to penetrate cell membranes and selectively bind cardiolipin, a phospholipid critical to the inner mitochondrial membrane. By stabilizing the electron transport chain, SS-31 aims to restore mitochondrial efficiency in conditions where mitochondrial dysfunction is a driver of disease.

SS-31 has progressed further in the clinical pipeline, with Phase 2 and 3 trials conducted in Barth syndrome, age-related macular degeneration, and heart failure with preserved ejection fraction. MOTS-c research remains primarily preclinical but is rapidly expanding.

Peptide Profiles

MOTS-c Profile SS-31 Profile

Citations

[1] Lee C. et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab. 2015 Source
[2] Lee C. et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab. 2015 Source
[3] MOTS-c prevents pancreatic islet cell senescence to delay diabetes — Exp Mol Med. 2025 Source
[4] MOTS-c restores mitochondrial respiration in type 2 diabetic heart — Frontiers Physiol. 2025 Source
[5] MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline — Nature Commun. 2021 Source
[6] MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications — Life Sciences 2026 Source
[7] FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee Source
[8] FDA Approves FORZINITY (elamipretide) for Barth Syndrome — Stealth BioTherapeutics, September 2025 Source
[9] UMDF — FDA Approves First Mitochondrial Disease Therapy Source
[10] Johns Hopkins Hub — FDA approves drug for Barth syndrome, September 2025 Source
[11] Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential — IJMS. 2026 Source
[12] SS-31 treatment ameliorates cardiac mitochondrial morphology in Barth syndrome model — Scientific Reports. 2024 Source